Keapstone Therapeutics

www.keapstone.com

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor Neuron Disease (MND) – which together affect more than 130,000 people in the UK. Keapstone was co-founded in February 2017 by the University of Sheffield, Parkinson’s UK and Dr Richard Mead and Prof Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN). The company combines world-leading research from the university with funding and expertise from Parkinson’s UK and consultants and discovery partners with extensive drug development expertise.

Read more

Reach decision makers at Keapstone Therapeutics

Lusha Magic

Free credit every month!

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor Neuron Disease (MND) – which together affect more than 130,000 people in the UK. Keapstone was co-founded in February 2017 by the University of Sheffield, Parkinson’s UK and Dr Richard Mead and Prof Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN). The company combines world-leading research from the university with funding and expertise from Parkinson’s UK and consultants and discovery partners with extensive drug development expertise.

Read more
icon

Employees

1-10

icon

Founded

2017

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Founding Scientist and Director

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(5)

Reach decision makers at Keapstone Therapeutics

Free credits every month!

My account

Sign up now to uncover all the contact details